NKMAX Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
NKMAX's earnings have been declining at an average annual rate of -8.7%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 7.6% per year.
Anahtar bilgiler
-8.7%
Kazanç büyüme oranı
-5.2%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 11.7% |
Gelir büyüme oranı | 7.6% |
Özkaynak getirisi | -19.4% |
Net Marj | 149.3% |
Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Gelir ve Gider Dağılımı
NKMAX nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Mar 24 | 10,475 | 15,644 | 43,192 | 8,062 |
31 Dec 23 | 10,769 | 5,261 | 48,277 | 9,441 |
30 Sep 23 | 10,945 | -66,609 | 43,773 | 9,819 |
30 Jun 23 | 10,997 | -38,999 | 38,490 | 9,950 |
31 Mar 23 | 10,728 | -54,677 | 35,896 | 10,400 |
31 Dec 22 | 11,263 | -53,505 | 35,864 | 9,895 |
30 Sep 22 | 11,705 | -60,705 | 37,854 | 9,765 |
30 Jun 22 | 12,159 | -50,882 | 37,007 | 9,990 |
31 Mar 22 | 12,771 | -50,558 | 36,047 | 10,235 |
31 Dec 21 | 13,020 | -50,336 | 36,141 | 9,355 |
30 Sep 21 | 12,605 | -40,895 | 35,126 | 8,898 |
30 Jun 21 | 11,959 | -49,148 | 34,311 | 8,682 |
31 Mar 21 | 11,234 | -45,050 | 33,932 | 7,788 |
31 Dec 20 | 10,372 | -41,439 | 31,490 | 8,189 |
30 Sep 20 | 9,416 | -45,719 | 27,118 | 9,538 |
30 Jun 20 | 9,169 | -40,787 | 24,187 | 8,738 |
31 Mar 20 | 8,722 | -16,107 | 21,277 | 7,522 |
31 Dec 19 | 8,749 | -11,429 | 18,921 | 6,505 |
30 Sep 19 | 7,825 | -5,344 | 15,980 | 4,932 |
30 Jun 19 | 7,085 | -4,278 | 14,400 | 4,300 |
31 Mar 19 | 6,824 | -22,058 | 14,174 | 4,479 |
31 Dec 18 | 6,269 | -20,453 | 13,577 | 4,655 |
30 Sep 18 | 5,913 | -20,318 | 14,642 | 5,120 |
30 Jun 18 | 5,677 | -18,885 | 14,917 | 5,203 |
31 Mar 18 | 5,155 | -17,473 | 14,395 | 5,118 |
31 Dec 17 | 4,830 | -16,632 | 13,853 | 5,093 |
30 Sep 17 | 7,253 | -9,969 | 12,668 | 3,656 |
30 Jun 17 | 7,091 | -5,866 | 11,431 | 3,545 |
31 Mar 17 | 6,855 | -4,960 | 9,768 | 3,688 |
31 Dec 16 | 6,876 | -4,837 | 9,120 | 3,913 |
30 Sep 16 | 4,140 | -7,228 | 7,838 | 3,835 |
30 Jun 16 | 3,578 | -8,390 | 7,242 | 3,769 |
31 Mar 16 | 3,228 | -5,593 | 5,404 | 3,108 |
31 Dec 15 | 2,513 | -5,374 | 5,223 | 2,724 |
30 Sep 15 | 2,001 | -5,970 | 5,326 | 2,597 |
30 Jun 15 | 1,777 | -5,850 | 4,442 | 2,471 |
31 Mar 15 | 1,732 | -6,166 | 4,225 | 2,484 |
31 Dec 14 | 1,678 | -5,840 | 3,760 | 2,313 |
31 Dec 13 | 1,503 | -3,181 | 2,562 | 732 |
Kaliteli Kazançlar: A182400 has a high level of non-cash earnings.
Büyüyen Kar Marjı: A182400 became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A182400 has become profitable over the past 5 years, growing earnings by -8.7% per year.
Büyüme Hızlandırma: A182400 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: A182400 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Özkaynak Getirisi
Yüksek ROE: A182400's Return on Equity (-19.4%) is considered low.